Lupus Nephritis Clinical Trial Landscape

Recent Developments in Lupus Nephritis Treatment

The lupus nephritis pipeline has experienced several notable developments in recent years, reflecting accelerating innovation across biologics, immunotherapies, and cellular approaches.

In February 2026, Fate Therapeutics announced that it was progressing toward the initiation of its first planned Phase II clinical trial in lupus nephritis. The development represents an important step in the company's efforts to advance its cell therapy platform into later-stage clinical evaluation for autoimmune diseases.

In October 2025, Adicet Bio, Inc. reported initial safety and efficacy findings from the first seven patients treated with ADI-001 in an ongoing Phase I study evaluating the candidate in autoimmune diseases. The findings contributed to growing interest in the potential of engineered cellular therapies for immune-mediated conditions, including lupus nephritis.

In June 2025, findings from the Phase III REGENCY trial (NCT04221477) indicated that obinutuzumab combined with standard therapy provided greater efficacy than standard therapy alone in patients with lupus nephritis. The results, reported by Richard A. Furie, MD, and colleagues, were published in the New England Journal of Medicine and added further evidence supporting B-cell-directed strategies in lupus nephritis.

In May 2025, AbelZeta Pharma, Inc. announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to C-CAR168 for refractory systemic lupus erythematosus, including lupus nephritis. The designation underscores the increasing regulatory attention surrounding advanced cellular therapies for difficult-to-treat autoimmune disorders.

Earlier, in April 2025, Fate Therapeutics announced that the FDA granted Regenerative Medicine Advanced Therapy designation to FT819, an investigational cell therapy being developed for active moderate-to-severe systemic lupus erythematosus, including lupus nephritis. Such regulatory designations can facilitate closer interaction between developers and regulators and potentially support more efficient clinical development.

Comprehensive Scope of the Lupus Nephritis Pipeline Report

DelveInsight’s lupus nephritis pipeline report provides global coverage of therapeutic development and evaluates candidates according to multiple dimensions. The assessment includes products being developed as monotherapies, combination therapies, and candidates with potential for both mono and combination use.

The report evaluates therapies across discovery, preclinical, Phase I, Phase II, and Phase III development stages, enabling stakeholders to understand pipeline maturity and identify potential opportunities across the development continuum.

Therapeutics are also assessed according to their routes of administration, including oral, intravenous, subcutaneous, parenteral, and topical delivery. Molecular classifications covered in the analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers, and gene therapies.

Mechanism-of-action analysis covers BAFF-R inhibitors, interleukin-2 replacements, EBI2 antagonists, anti-CD19 therapies, CD19 CAR-NK approaches designed to eliminate B cells, anti-CD20 therapies, and other emerging mechanisms.